[{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sulfasalazine","moa":"||Arachidonate 5-lipoxygenase | Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Otilimab","moa":"||G-CSF receptor","graph1":"Immunology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"||Dihydrofolate reductase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CC-99677","moa":"||MK2 kinase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"University of Cambridge","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Proguanil","moa":"||SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Cambridge","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Cambridge \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"University of Cambridge \/ Inapplicable"},{"orgOrder":0,"company":"Anabio R&D","sponsor":"Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"||Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Anabio R&D","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anabio R&D \/ Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy","highestDevelopmentStatusID":"1","companyTruncated":"Anabio R&D \/ Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy"}]

Find Clinical Drug Pipeline Developments & Deals for Azulfidine EN-tabs

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Access all COS suppliers
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Azulfidine EN-tabs

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

30 API Suppliers, 12 USDMF, 5 CEP/COS, 3 JDMF, 2 EU WC, 8 KDMF, 10 NDC API, 6 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

48 FDF Dossiers, 16 FDA Orange Book, 12 Europe, 6 Canada, 6 Australia, 2 South Africa, 6 Listed Dossiers

RELATED EXCIPIENT COMPANIES

1 Minakem, 5 SPI Pharma, 1 DKSH, 4 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 1 Actylis, 1 Aeon Procare, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 13 BASF, 2 CD Formulation, 1 Corel Pharma Chem, 4 DFE Pharma, 1 Finar, 6 Gangwal Chemicals, 1 Ideal Cures, 4 Ingredion Pharma Solutions, 1 Kerry, 3 Keval Exports, 10 Microlex e.U, 3 Nitika Pharmaceutical Specialities, 1 Novo Excipients, 4 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 20 Roquette, 1 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 11 Sigachi Industries, 4 Silverline Chemicals, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

44 Fillers, Diluents & Binders, 27 Disintegrants & Superdisintegrants, 23 Lubricants & Glidants, 17 Direct Compression, 15 Thickeners and Stabilizers, 15 Granulation, 12 Co-Processed Excipients, 11 Coating Systems & Additives, 11 Solubilizers, 9 Controlled & Modified Release, 9 Film Formers & Plasticizers, 7 Chewable & Orodispersible Aids, 6 Topical, 5 Taste Masking, 4 Emulsifying Agents, 3 Parenteral, 2 Rheology Modifiers, 2 API Stability Enhancers

DIGITAL CONTENT

5 News #PharmaBuzz

5 News #PharmaBuzz

GLOBAL SALES INFORMATION

7 US Medicaid Prescriptions, 8 Regulatory FDF Prices

MARKET PLACE

20 APIs, 3 FDF Dossiers

REF. STANDARDS & IMPURITIES

3 EDQM, 2 Others

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Sanofi

France

ChemOutsourcing

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Sarilumab,Azathioprine,Chloroquine Phosphate,Hydroxychloroquine Sulphate,Leflunomide,Methotrexate,Sulfasalazine

Therapeutic Area : Immunology

Study Phase : Phase IV

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

February 28, 2018

Lead Product(s) : Sarilumab,Azathioprine,Chloroquine Phosphate,Hydroxychloroquine Sulphate,Leflunomide,Methotrexate,Sulfasalazine

Therapeutic Area : Immunology

Highest Development Status : Phase IV

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Sanofi

France

ChemOutsourcing

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Sarilumab,Sulfasalazine,Leflunomide,Bucillamine,Tacrolimus,Mizoribine

Therapeutic Area : Immunology

Study Phase : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese P...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

February 26, 2015

Lead Product(s) : Sarilumab,Sulfasalazine,Leflunomide,Bucillamine,Tacrolimus,Mizoribine

Therapeutic Area : Immunology

Highest Development Status : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

03

Sanofi

France

ChemOutsourcing

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Sarilumab,Methotrexate,Sulfasalazine,Leflunomide,Hydroxychloroquine Sulphate

Therapeutic Area : Immunology

Study Phase : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

February 07, 2014

Lead Product(s) : Sarilumab,Methotrexate,Sulfasalazine,Leflunomide,Hydroxychloroquine Sulphate

Therapeutic Area : Immunology

Highest Development Status : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

04

Sanofi

France

ChemOutsourcing

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Sarilumab,Hydroxychloroquine Sulphate,Methotrexate,Sulfasalazine,Leflunomide

Therapeutic Area : Immunology

Study Phase : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who A...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

January 15, 2013

Lead Product(s) : Sarilumab,Hydroxychloroquine Sulphate,Methotrexate,Sulfasalazine,Leflunomide

Therapeutic Area : Immunology

Highest Development Status : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

05

Sanofi

France

ChemOutsourcing

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Sarilumab,Hydroxychloroquine Sulphate,Methotrexate,Sulfasalazine,Leflunomide

Therapeutic Area : Immunology

Study Phase : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Respondin...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

October 18, 2012

Lead Product(s) : Sarilumab,Hydroxychloroquine Sulphate,Methotrexate,Sulfasalazine,Leflunomide

Therapeutic Area : Immunology

Highest Development Status : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

06

Anabio R&D

Country

EPSC

Not Confirmed

07

MorphoSys

Germany

EPSC

Not Confirmed

08

Bristol Myers Squibb

U.S.A

EPSC

Not Confirmed

09

University of Cambridge

Country

EPSC

Not Confirmed

10

Galapagos

Belgium

EPSC

Not Confirmed

1
2
3